Raloxifene Hydrochloride
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Raloxifene Hydrochloride |
| DrugBank ID | DB00481 |
| Brand Names (EU) | Raloxifene Teva |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.72% |
Approved Indication (EMA)
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | duodenal ulcer (disease) | 99.72% | DL |
| 2 | obsolete susceptibility to ischemic stroke | 99.68% | DL |
| 3 | hypoalphalipoproteinemia | 99.65% | DL |
| 4 | duodenal obstruction | 99.64% | DL |
| 5 | duodenogastric reflux | 99.59% | DL |
| 6 | postmenopausal osteoporosis | 99.06% | DL |
| 7 | Worth syndrome | 98.97% | DL |
| 8 | homozygous familial hypercholesterolemia | 98.69% | DL |
| 9 | autosomal dominant neovascular inflammatory vitreoretinopathy | 98.56% | DL |
| 10 | pregnancy associated osteoporosis | 98.55% | DL |
| 11 | cerebral infarction | 98.22% | DL |
| 12 | brain stem infarction | 98.03% | DL |
| 13 | obsolete familial combined hyperlipidemia | 98.02% | DL |
| 14 | ABri amyloidosis | 97.55% | DL |
| 15 | amenorrhea (disease) | 97.44% | DL |
| 16 | succinyl-CoA:3-ketoacid CoA transferase deficiency | 97.38% | DL |
| 17 | cerebral artery occlusion | 97.10% | DL |
| 18 | cerebral arterial disease | 96.81% | DL |
| 19 | acne (disease) | 96.27% | DL |
| 20 | Prinzmetal angina | 95.77% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.